CAMBRIDGE, Mass. & EBERSBERG, Germany--(BUSINESS WIRE)--July 25, 2005--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has granted MWG Biotech AG, an established provider of synthetic nucleic acids, a non-exclusive license to provide research products and services in RNA interference (RNAi) under the Kreutzer-Limmer patent family owned by Alnylam. This patent family covers short interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells.
am 3.August kommt der Report und wie ich das sehe,verstehen sie zwar auf elegante Weise zu Geld zu kommen durch Ausgabe von 1/1000 Aktien zu 80$,aber sonst wohl wenig Umsatz
In May 2005, the EPO granted a new patent to Alnylam in the "Kreutzer-Limmer" patent family, with broad claims covering therapeutic compositions, methods, and uses of short interfering RNAs, the molecules that mediate RNAi, and derivatives with a length between 15 and 49 nucleotidesa ,a length that is a critical feature for siRNAs to be used in mammalian systems for harnessing the endogenous RNAi mechanism.. This was the second patent granted by the EPO in the Kreutzer-Limmer family, and significantly extended the scope of the original Kreutzer-Limmer patent granted in 2002.
